Originals

Archives of Gynecology and Obstetrics

, Volume 252, Issue 1, pp 49-53

Influence on erythropoietin levels of treatment with cisplatinum-endoxan

  • W. LechnerAffiliated withDepartment of Obstetrics and Gynecology, University of Innsbruck
  • , E. Artner-DworzakAffiliated withInstitute of Medical Chemistry, University of Innsbruck
  • , E. SölderAffiliated withDepartment of Obstetrics and Gynecology, University of Innsbruck
  • , M. SachsenmaierAffiliated withDepartment of Obstetrics and Gynecology, University of Innsbruck
  • , D. KölleAffiliated withDepartment of Obstetrics and Gynecology, University of Innsbruck
  • , H. MoncayoAffiliated withDepartment of Obstetrics and Gynecology, University of Innsbruck
  • , R. ReitsamerAffiliated withDepartment of Obstetrics and Gynecology, University of Innsbruck

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the erythropoietin concentrations returned to values similar to those before treatment started.

Key words

Erythropoietin Cytostatic agents Cisplatinum Endoxan